A hematologist’s guide to the most important abstracts at ASCO 2026

At the 2026 Annual Meeting of the American Society of Clinical Oncology, several hematologic malignancy abstracts stand out, not only because of their clinical relevance, but because they collectively reflect where the field is heading: earlier intervention, deeper immune-based responses, more personalized treatment strategies and novel approaches to overcoming resistance. Across multiple myeloma, leukemia, lymphoma and myeloproliferative neoplasms, these select studies highlight the accelerating transition toward immunotherapy-driven and biology-guided treatment paradigms. Advancing BCMA-targeted therapy in relapsed disease One of the clinically important and practice-changing studies is “MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator’s choice of pomalidomide,...